Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Exp Neurol. Author manuscript; available in PMC 2010 November 1.
Published in final edited form as:
PMCID: PMC2761527

Inhibition of CXCR2 signaling promotes recovery in models of Multiple Sclerosis


Multiple sclerosis (MS) is a neurodegenerative disease characterized by demyelination/remyelination episodes that ultimately fail. Chemokines and their receptors have been implicated in both myelination and remyelination failure. Chemokines regulate migration, proliferation and differentiation of immune and neural cells during development and pathology. Previous studies have demonstrated that the absence of the chemokine receptor CXCR2 results in both disruption of early oligodendrocyte development and long term structural alterations in myelination. Histological studies suggest CXCL1, the primary ligand for CXCR2, is upregulated around the peripheral areas of demyelination suggesting this receptor/ligand combination modulates responses to injury. Here we show that in focal LPC induced demyelinating lesions, localized inhibition of CXCR2 signaling reduced lesion size and enhanced remyelination while systemic treatments were relatively less effective. Treatment of spinal cord cultures with CXCR2 antagonists reduced CXCL1 induced A2B5+ cell proliferation and increased differentiation of myelin producing cells. More critically, treatment of myelin oligodendrocyte glycoprotein peptide 35-55-induced EAE mice, an animal model of multiple sclerosis, with small molecule antagonists against CXCR2 results in increased functionality, decreased lesion load, and enhanced remyelination. Our findings demonstrate the importance of antagonizing CXCR2 in enhancing myelin repair by reducing lesion load and functionality in models of multiple sclerosis and thus provide a therapeutic target for demyelinating diseases.

Keywords: oligodendrocyte, myelin repair, spinal cord, Multiple Sclerosis, remyelination, neuroinflammation


Multiple sclerosis (MS) is a devastating heterogeneous inflammatory demyelinating disorder of the central nervous system (CNS) affecting young adults (Davis, 1970; Antel, 1999; Compston and Coles, 2002; Benedict and Bobholz, 2007). Hallmarks of the disease include recurrent demyelinating episodes that result in the progression of neurological deficits due to the slowing and ultimately failure of axonal conduction (Davis, 1970; Waxman, 1977; Blakemore et al., 2000; Baumann and Pham-Dinh, 2001; Nashmi and Fehlings, 2001; Bjartmar et al., 2003). Remyelination frequently occurs during early stages of disease, however this fails during later disease stages and the number of persistent demyelinating lesions increases (Chari, 2007).

The majority of current therapies for MS target the inflammatory response that is distinctive of the disease (Miller et al., 1998; Hohol et al., 1999; Miller et al., 1999; McFarland and Martin, 2007; Trapp and Nave, 2008). Although active inflammation predominates in the initial stages of the disease, the neurological disabilities associated with the chronic disease accumulates independent of inflammatory mediators (McFarland and Martin, 2007; Frohman et al., 2008) and long-term recovery requires myelin repair. Models of MS include the experimental autoimmune encephalomyelitis (EAE) (Cross et al., 1991), where widespread demyelination is largely a consequence of immunological attack on resident CNS myelin following immunization by specific myelin peptides. Focal demyelinated lesions can be induced by direct injection of lysolecithin (LPC) (Ousman and David, 2000; Bambakidis et al., 2003; Mi et al., 2005) where demyelination is largely a consequence of chemical dissolution of myelin sheaths. Finally, cuprizone intoxication (Zatta et al., 2005) results in demyelination largely as a consequence of metabolic perturbations. In the present study, we utilize lysolecithin lesions and MOG35-55 peptide induced EAE to assess the efficacy of inhibiting the CXCR2 chemokine receptor in mediating demyelination and remyelination.

Chemokines, or chemoattractant cytokines, comprise a family of inducible secreted molecules of small molecular weight (8-10kDa) (Hesselgesser and Horuk, 1999; Fernandez and Lolis, 2002; Laing and Secombes, 2004), that function as activators of leukocytes, wound healing, modulators of angiogenesis, and tumorigenesis (Robinson et al., 2001; Smith et al., 2005; Charo and Ransohoff, 2006). The functions of chemokines have been primarily implicated in modulation of immune coordination and inflammation (Fernandez and Lolis, 2002; Flynn et al., 2003; Laing and Secombes, 2004; Charo and Ransohoff, 2006) where they contribute to the localization of specific cells with fine spatio-temporal precision (Charo and Ransohoff, 2006). Chemokine receptors are G-protein coupled receptors (GPCRs) usually linked to pertussis toxin sensitive Gi proteins (Bajetto et al., 2001). The receptor CXCR2 is the primary mediator of signaling by the chemokine CXCL1 (Katancik et al., 2000), a soluble secreted chemoattractive molecule of the ELR family of CXC chemokines. Their interaction initiates intracellular processes that modulate a number of cellular events, including migration, proliferation, and differentiation (Bajetto et al., 2001; Miller, 2002; Tsai et al., 2002). Several studies have characterized the expression and function of chemokine receptors on neural cells in the vertebrate CNS. For example, the CXCR4 receptor and its cognate ligand SDF1 have been implicated in the control of neuronal precursors in the hippocampus and cortex (Imitola et al., 2004). During oligodendrocyte development, signaling through CXCR2 in combination with platelet derived growth factor AA promotes oligodendrocyte precursor proliferation (Robinson et al., 1998; Robinson et al., 2001; Woodruff et al., 2004). Furthermore, the CXCR2 signaling pathway contributes to the correct localization of oligodendrocytes in white matter tracts of the spinal cord (Miller, 2002; Tsai et al., 2002; Padovani-Claudio et al., 2006).

Elevated levels of CXC chemokine expression are associated with a range of pathological CNS insults including infection, tumors, ischemia and demyelination (Liu et al., 1993; Spanaus et al., 1997; Filipovic et al., 2003; Keane et al., 2004; Sue et al., 2004; Omari et al., 2006; Valles et al., 2006) and this may reflect ingress of immune cells in response to local expression. For example, overexpression of CXCL1 in oligodendrocytes induces neutrophil invasion and astrogliosis (Tani et al., 1996; Tanabe et al., 1997). Overexpression of CXCL1 in astrocytes resulted in a milder course of EAE disease pathology (Omari et al., 2009) and upregulation of CXCL1 has been reported at the periphery of MS lesions coincident with the accumulation of OPCs (Omari et al., 2005). Furthermore, proliferation of OPCs has been determined in organotypic human fetal slice cultures to be dependent on CXCL1/CXCR2 signaling (Filipovic and Zecevic, 2008). By contrast, CXCR2 null animals have been reported to have increased NG2+ cells that may facilitate recovery of demyelination (Padovani-Claudio et al., 2006). Here we demonstrate that in a chemical demyelination model (LPC), and an immune mediated demyelination model (MOG35-55 peptide induced EAE), blocking CXCR2 enhances recovery and remyelination in spinal cords of affected animals suggesting inhibition of CXCR2 may represent a potential target for myelin repair.


Animals and Induction of EAE

All animal procedures were conducted according to approved guidelines established by the National Institutes of Health Animal Protection Guidelines and were approved by Institutional Animal Care and Utilization Committee of Case Western Reserve University School of Medicine

The chronic EAE model was induced in C57BL/6 mice using synthetic myelin oligodendrocyte glycoprotein peptide (MOG35-55, 200ul at 200μg/animal). Mice were injected subcutaneously with an emulsion of MOG35-55 peptide mixed with complete Freud's adjuvant with 500μg Mycobacterium tuberculosis followed by two intraperitoneal (IP) injections of 500μg pertussis toxin, one immediately after immunization and a second 24hrs later (Bai et al., 2009). Clinical scores were obtained on a 5 point scoring system in which a score of 0 equates to no clinical symptoms ; 1, limp tail; 2, paralysis of one limb; 3, paralysis of two hind limbs; 4, paralysis of front limbs; 5, death as previously described (Bai et al., 2009). Treatment of animals with either CXCR2 antagonist (Tocris; 20ng/kg) or vehicle was begun when the animals showed the initial signs of disease. In general, this occured 10-14 days post immunization. Animals received IP injections daily for the remainder of the study or two weeks post disease induction.

Lysolecithin induced demyelination and delivery of antagonists

Twelve week old female Sprague-Dawley rats (220-240 grams) were anesthetized with ketamine hydrochloride, xylazine hydrochloride, and acepromazine. Following a laminectomy at thoracic vertebrae level 10, three microliters of 1 percent LPC (L-α-lysophosphatidyl-choline, lysolecithin) (Sigma, St. Louis, MO) in 0.9 % sodium chloride solution were microinjected using a pulled glass pipette into the dorsal column of the spinal cord at a rate of 0.25 μl/min . Post-operatively, animals received a subcutaneous injection of 5ml of saline to promote hydration. For double injection of either CXCR2 neutralizing antibody (R&D systems, 100μg/ml) or CXCR2 antagonist (Tocris, 100μg/ml) or appropriate vehicle controls, animals were anesthetized 2 days post lesion and injected with either 3μl CXCR2 antibody or 3μl CXCR2 antagonist, using the same paradigm as above. Systemic delivery of CXCR2 antagonist (Tocris, 20ng/kg) was performed IP on the day of surgery and everyday thereafter. Animals were then allowed to recover for 10 days prior to sacrifice. Control animals received an equivalent injection of either isotype control antibody or vehicle.

Primary spinal cord cultures

Mixed cell cultures were prepared from postnatal day 3 rat spinal cords and plated on poly-L-lysine (PLL) coated coverslips. The media was changed the following day and cells allowed to grow for 3 days. Cells were grown in media consisting of DMEM, 10ng/ml platelet derived growth factor AA (PDGFAA), 10ng/ml fibroblast growth factor (bFGF), 1% FBS, and N2 supplement. Cells were treated with small molecule inhibitor against CXCR2 at various concentrations (40ng/ml, 80ng/ml, 160ng/ml) and/or the ligand CXCL1 (0.5 ng/ml) overnight and the effect on OPC development assessed.

Immunocytochemistry of primary cell cultures

Cells were fixed in 4% paraformaldehyde and incubated in primary antibody for 30 minutes in PBST (0.03% triton) (MBP: SMI99, Sternberger Monoclonals, 1:500) followed by corresponding secondary antibodies and mounted using Vectashield with DAPI (Vector Laboratories Burlingame, CA). Labeling with O4, A2B5 and O1 was performed on live cells. Cells were post-fixed using 5% acetic acid in methanol. To analyze proliferation of cells in S phase, bromodeoxyuridine (BrdU) (10μM) was added to the media at least 18 hours prior to fixation. Images were collected using a Leica DM5000B microscope and Leica Applications Suite Software. The proportion of each different cell type relative to the total number of DAPI positive cells were counted by an observer blinded to the treatment from 6 randomly selected fields taken from at least 2 different coverslips from 4 separate preparations. The data were pooled and presented at mean +/− standard deviation.

Immunohistochemistry and immunofluorescence

Animals were perfused with 4% PFA in saline. Transverse frozen sections of spinal cord were dried on slides and stored at −80°C. Sections were rinsed blocked in 0.03% PBST and 5% NGS and incubated in primary antibody overnight at 4°C (GFAP: Dako 1:500; Iba1: Wako 1:250; MBP: SMI99, Sternberger Monoclonals 1:500, Iba1: Dako, 1:100, ED1: Santa Cruz, 1:100). Sections were rinsed and incubated in anti-rabbit IgG or anti-mouse IgG fluorescently conjugated secondary antibodies (Sigma, 1:500) for 1 hour at room temperature followed by 10 minutes in DAPI (1:1000; Invitrogen) to label nuclei. The sections were briefly rinsed and mounted using Citifluor mounting media (Ted Pella, Redding PA). Images were collected using a Leica DM5000B microscope and Leica Applications Suite software. The number of Iba1 positive cells were counted in defined regions of spinal cord grey and white matter to determine relative amount of microglia and macrophages in response to CXCR2 treatment in EAE animals. The mean cell number was determined from at least 4 different sections taken from 2 different animals. Data was pooled and presented as mean+/− standard deviation.

Electron Microscopy

Animals were anesthetized and perfused initially with PBS followed by 3% formaldehyde/3% gluteraldehyde in 0.1M sodium cacodylate buffer, pH 7.4 (Electron Microscopy Sciences, Hatfield, PA). Tissue was dissected and 300μm thick vibratome sections post fixed in 1% OsO4. Samples from EAE animals were taken from lumbar segments of the spinal cord. Sections from lysolecithin (LPC) animals were selected from midlesion as indicated by luxol fast blue staining as previously described (Mi et al., 2005). Sections were dehydrated through a series of ethanol dilutions, stained using uranyl acetate and embedded in a Poly/Bed812 resin (Polysciences Inc., Warrington, PA). Thin (1μm) sections were stained with toluidine blue and appropriate areas for ultrathin sectioning were selected. Ultrathin (0.1μm) from matching areas of experimental and control tissue blocks were cut and visualized using an electron microscope (JEOL1200CX) at 80kV. G ratios were calculated by dividing the axonal area and myelin thickness for randomly selected myelinated axons. Three separate measurements of radial thickness of myelin were taken for each axon and averaged to provide mean myelin thickness.

Statistical analyses

Data was analyzed using t-test assuming equal variances in Microsoft Excel software. Statistical significance was set to p<0.05. Values are described in the text as mean +/− standard deviation followed by the p-value, and plotted either as mean +/− standard deviation or mean +/− two standard errors of the mean.


Local delivery of CXCR2 blocking reagents reduce the size of LPC-induced lesions

To determine whether CXCR2 antagonists alter the rate of recovery in models of demyelination and remyelination, the effect of local injection of neutralizing anti-CXCR2 antibody on lesion load was assayed in a lysolecithin model (Bambakidis et al., 2003; Mi et al., 2005). Lysolecithin injection induces rapid local demyelination that is mostly developed by 2 days post injection. Direct injection of a CXCR2 neutralizing antibody into a region adjacent to the lesion 2 days after LPC injection had a profound effect on lesion volume (Fig 1). Animals that received control antibodies had a lesion volume of 5 +/− 2.8mm3 after a survival of 10 days and the lesions appeared to contain relatively little myelin (Fig 1 A,C, E, and G). By contrast, in animals that received neutralizing CXCR2 antibodies, the lesion size was reduced to 1+/− 1.3mm3 after 10 days and only the central core was devoid of myelin (Fig 1 B, D, F, and G). Three dimensional reconstruction of the area of the lesion occupying the spinal cord revealed a reduction in rostral caudal and lateral extent of the lesion in anti-CXCR2 treated animals although the lesions still spanned the depth of the dorsal column (Fig 1 F and G) (n=5). To confirm the specificity of the anti-CXCR2 antibody effects, the studies were repeated using a single injection of a small molecule CXCR2 inhibitor. Local injection of the Tocris CXCR2 antagonist (Busch-Petersen, 2006) resulted in smaller LPC lesions and increased number of myelinated axons at 10 days post insult (Fig 2). For example, the proportion of myelinated fibers was less than 6 +/− 4% in the middle lesion of animals that received vehicle only (Fig 2 A, C and E) and there were substantial cellular infiltrates throughout the lesion while similar areas of CXCR2 antagonist treated animals (Fig 2 B, D and E) contained a significant proportion (54 +/− 7%) of remyelinated axons scattered throughout the lesion and fewer infiltrated cells. Ultrastructural studies confirmed the presence of relatively thinly myelinated axons (arrows) scattered throughout the lesion (Fig 2D). The lesions that develop in response to LPC injections are primarily a result of direct chemical demyelination rather than immune cell infiltration (Ousman and David, 2000) and these studies suggest that treatment with CXCR2 antagonists significantly accelerates myelin repair in a non-inflammatory setting through a mechanism that likely includes a direct effect on oligodendrocytes and their precursors (Robinson et al., 1998; Tsai et al., 2002).

Figure 1
Local delivery of anti-CXCR2 antibodies reduces the size of LPC induced demyelinated lesions
Figure 2
Local delivery of CXCR2 antagonists enhances remyelination in LPC lesions

Systemic delivery of CXCR2 antagonist does not significantly enhance recovery of LPC induced demyelination

To determine whether CXCR2 inhibition in the LPC lesions was primarily local or systemic, the CXCR2 antagonist was delivered IP directly after lysolecithin lesions (Fig 3). Injection of CXCR2 antagonist daily for 10 days after induction of a dorsal spinal cord LPC lesion had only a small effect on lesion volume (2.6mm in experimental versus 3mm in controls). Consistent with this limited effect of systemic blockade of CXCR2 on lesion size, morphological studies demonstrated only a marginal although significant effect on repair in the LPC model. In middle areas of lesions in control animals (Fig 3C) 94 +/− 2% of the axons were demyelinated (asterisks) and 6+/−3% were myelinated, similarly in animals that received CXCR2 antagonists (Fig 3D) 76+/−4% axons were demyelinated while 24 +/− 6% were remyelinated (arrows) (p=0.004)(Fig 2E, Fig 3). In all cases the total number of axons and the proportion that were affected by LPC injection were not different suggesting there is not a protective effect on lesion formation following systemic inhibition of CXCR2. Further analyses suggested no significant difference in MBP expression in the lesion or cellularity of the lesion with systemic CXCR2 inhibition (data not shown) suggesting that the primary benefit derived from direct injections reflected local inhibition of CXCR2 signaling on CNS cells.

Figure 3
Systemic delivery of CXCR2 antagonists has limited effect on repair of LPC lesions

CXCR2 antagonists decrease CXCL1 induced OPC proliferation and increases OPC differentiation in vitro

Previous studies suggest that OPCs express the CXCR2 receptor and respond directly to CXCL1 stimulation (Robinson et al., 1998; Tsai et al., 2002). To assess whether CXCR2 antagonists had direct effects on neural cells, the antagonist was added to spinal cord cultures to determine the effect on oligodendrocyte differentiation (Fig 4). Spinal cord cultures from P3 animals were grown for 3 days and treated for one day with CXCL1 (Fig 4 B,E, and H), the CXCR2 antagonist (Fig 4 C, F, and I) or control medium (Fig 4 A, D, and G). Oligodendrocyte precursors were identified through binding of mAb A2B5. In the presence of CXCL1 (0.5ng/ml), the proportion of A2B5+ cells increased dramatically due to proliferation (46% p=0.002) (Fig 4B). This increase was abolished by treatment with CXCR2 antagonist (26%) and the residual cells were weakly A2B5+ and appeared to have a larger cell body and more differentiated phenotype suggesting treatment with CXCR2 antagonist promoted OPC differentiation (Fig 4C). Cultures exposed to CXCR2 antagonist contained increased O1+cells (20 +/− 4% versus 34 +/−3%) and 50% more MBP positive cells than those in control conditions (18 +/− 1% versus 52 +/− 5% p=0.007) (Fig 4 D-I). Not only were there increased number of differentiated oligodendrocytes but their morphology was also substantially different. More of the MBP+ cells contained sheet like processes in the presence of CXCR2 antagonist than in control conditions (Fig 4I). Consistent with previous studies (Tsai et al., 2002) the presence of CXCR2 antagonists reduced the proliferation of A2B5+ cells (42 +/− 4% BrdU+/A2B5+ cells) in the presence or absence of CXCL1 (data not shown). These data indicate that the CXCR2 antagonist blocks the mitogenic effects of CXCL1 and facilitates OPC differentiation.

Figure 4
Inhibition of CXCR2 promotes the differentiation of spinal cord OPCs in vitro

Functional improvement in EAE mice treated with CXCR2 antagonist

While analyses of recovery from lysolecithin (LPC) lesions has many advantages for the study of myelin repair, the immunological aspects of demyelinating disease such as MS are effectively modeled by experimental allergic encephalitis (EAE). Previous studies have implicated CXCR2 in the progression of EAE (Carlson et al., 2008) and to investigate whether systemic treatment with CXCR2 antagonists reduced disease burden, animals immunized with the MOG35-55 peptide (Bai et al., 2009) were treated daily with 20ng/kg CXCR2 antagonist (Tocris) while control animals received vehicle only (Fig 5). Treatments were initiated when immunized animals began to show functional deficits. On average this occurred during the second week following immunization. Animals that received vehicle rapidly developed increasing functional deficits (Fig 5A). EAE animals initially presented with flaccid tail and hindlimb weakness that progressed over a three-week period to forelimb paralysis. Some animals were severely compromised by day 24 and were subsequently sacrificed. By contrast, animals that received CXCR2 antagonists initially demonstrated functional deficits including hindlimb weakness but, with continued treatment, all animals (n=12) exhibited some functional recovery and no animals progressed to forelimb paralysis. Indeed, a subset (9/12) of animals had total functional recovery after two weeks of treatment (Fig 5A). These data suggest that even after the onset of disease antagonizing CXCR2 signaling promotes functional recovery in a chronic model of EAE.

Figure 5
Systemic inhibition of CXCR2 results in functional improvement in MOG35-55 peptide induced EAE animals

Enhanced myelination and reduced lesion load in EAE mice treated with CXCR2 inhibitor

Histological analyses of CXCR2 antagonist and vehicle treated EAE animals supported the functional assessment. Animals treated with the CXCR2 antagonist had a reduced lesion load in the spinal cord. Luxol fast blue staining showed smaller demyelinated lesions after 14 days of treatment with CXCR2 antagonist (Fig 5C) compared to vehicle controls (Fig 5B). Although CXCR2 treated animals were not entirely free of demyelinated lesions, quantitation of relative lesion load by 3D reconstruction of the area occupied by lesions demonstrated a reduction of 39 +/− 2 % (3.3mm3 vehicle versus 1.3mm3 CXCR2 antagonist treated animals) in the extent of spinal cord demyelination between the EAE control and CXCR2 antagonist treated animals (Fig 5F; p=0.001). Ultrastructural analyses confirmed that following 14 days of treatment with CXCR2 antagonist, lesion areas from treated animals contained larger numbers of remyelinated axons (Fig 6 D and E) than non-treated EAE controls (Fig 6 C and E). For example, while greater than 90% of the axons were demyelinated (asterisks) in lesion areas from non-treated EAE animals less than 25% of axons were demyelinated in antagonist treated animals (Fig 6; p<0.0001). Many of the myelinated axons in treated animals had altered G ratios consistent with remyelination (Fig. 6F). Vehicle only treated EAE animals had a ratio close to 1 suggesting the myelinated axons were not remyelinated. By contrast, CXCR2 antagonist treated animals had a mean ratio closer to 3 indicative of significantly thinner myelin sheaths which indicates remyelination (Figure 6F; p=0.02). To confirm the effects of blocking CXCR2 on demyelination/remyelination, sections from control and treated EAE animals were labeled with antibodies to the major myelin protein MBP (Fig 7). Inhibition of CXCR2 increased the intensity of MBP labeling by 63% over control EAE animals (Fig 7 A-D and reduced the size of the demyelinated areas) suggesting that oligodendrocytes are being recruited and/or protected in lesion areas by reducing CXCR2 signaling.

Figure 6
Systemic inhibition of CXCR2 results in decreased cell infiltration and increased remyelination in MOG35-55 induced EAE
Figure 7
Systemic treatment with CXCR2 antagonists result in increased MBP and decreased Iba1 expression in EAE animals

Infiltration and activation of macrophage/microglial cells are reduced in MOG35-55 induced EAE animals treated with CXCR2 inhibitors

The reduction in demyelinated areas in CXCR2 antagonist treated EAE animals correlated with a reduction in inflammatory cell infiltration. For example, H&E stained sections from vehicle EAE animals revealed substantial cell infiltrates associated with lesion areas (Fig 5D) characteristic of lesion pathology and the recruitment of immune cells. By contrast, in animals treated with the CXCR2 inhibitor only rare mononuclear cells were seen in presumptive lesion areas (Fig 5E).

The preservation of cytoarchitecture and reduction in vascular cuffing was most clearly seen in toluidine blue stained 1 μm sections (Fig 6 A and B) and confirmed at the ultrastuctural level. Vehicle treated EAE animals (Fig 6A) had significant cuffing and infiltration while CXCR2 antagonist treated EAE animals (Fig 6B) exhibited fewer cells around blood vessels and infiltration into the parenchyma of the spinal cord. Microglia were present in all spinal cords but their reactivity, defined by a more stellate phenotype and shorter process, was reduced in animals treated with CXCR2 antagonists (Fig 7 E-H). Vehicle-treated EAE animals contained large numbers of Iba1+ cells within lesions (Fig 7E) as well as in adjacent grey and white matter areas of the spinal cord. Animals treated with CXCR2 antagonists, however, demonstrated microglial activation associated with smaller lesions and a 50+/− 5% decrease of Iba1 cells in adjacent grey and white matter regions (Fig 7 F and H). EAE animals that were removed from treatment after 1 week exhibited a return of demyelination in the absence of inflammation (Fig 8B). These animals also exhibited a return in functional impairment associated with demyelination (data not shown). In contrast, EAE animals that were treated with CXCR2 antagonists for a longer period of time (2 weeks), demonstrated an enhancement in remyelination in toluidine blue sections (Fig 8A) although they retained some inflammatory cell infiltration into the parenchyma of the spinal cord (Fig 8A). Taken together, our studies suggest that antagonism of CXCR2 signaling promotes functional recovery and facilitates the establishment of normal cytoarchitecture in the spinal cord in animal models of CNS demyelination.

Figure 8
Long-term but not short-term treatment with CXCR2 antagonist results in sustained remyelination


Current therapies for demyelinating diseases such as MS are largely focused on regulating the immunological attack on neural tissue. Successful long term functional recovery in MS is likely to require substantial myelin repair. Here we demonstrate that blocking signaling through the chemokine receptor CXCR2 promotes functional recovery in two demyelinating models and OPC differentiation is enhanced. Focal injections of CXCR2 antibody, or a CXCR2 antagonist, enhanced myelin repair in LPC lesions and promoted the differentiation of OPCs in culture. Systemic injection of CXCR2 antagonist resulted in limited enhancement of repair most likely reflective of the limited involvement of immune cells in this model. Consistent with this hypothesis, systemic treatment with CXCR2 antagonist resulted in significant functional recovery in a model of chronic EAE. This functional recovery was correlated with a reduced disease burden. For example, compared to vehicle treated EAE animals, those that received daily IP injections of CXCR2 antagonist had smaller demyelinated lesions and higher levels of myelin basic protein expression in the spinal cord that was correlated with higher numbers of remyelinated axons. Treatment with CXCR2 antagonist also reduced the extent of microglial activation and the degree of inflammatory cell infiltration.

The enhanced recovery from CNS demyelinating lesions mediated by antagonists of CXCR2 likely reflects influences on both neural and immune cells. Within the CNS, CXCR2 has been reported to be expressed on a range of cells including OPCs and other glia (Luo et al., 2000; Nguyen and Stangel, 2001). Within the spinal cord oligodendrocyte lineage, stimulation of CXCR2 on A2B5+ OPCs results in enhancement of PDGF driven proliferation and inhibition of cell migration (Tsai et al., 2002; Kadi et al., 2006). The accelerated repair in LPC lesions following local inhibition of CXCR2 signaling may reflect the ability of OPCs to ignore the migrational blockade from locally expressed CXCL1 and effectively repopulate the lesion. Alternatively, in order to progress to myelination, OPCs must complete their differentiation and mature. The control of differentiation has been shown to be inversely correlated with proliferation. If OPCs are refractory to the mitogenic stimulation of CXCL1 through CXCR2 blockade, they are more likely to differentiate and myelinate. Consistent with this hypothesis, inhibition of CXCR2 in spinal cord cultures resulted in enhanced numbers of mature MBP+ oligodendrocytes. Other neural cells have also been reported to express CXCR2 receptors including astrocytes. Astrocytes are thought to be a potential source of the ligand, raising the possibility of an autocrine loop that also contributes to the regulation of remyelination either through release of CXCL1 or other cytokines.

The robust functional recovery seen in EAE models after systemic delivery of CXCR2 antagonists may reflect CXCR2 signaling responses in immune tissues. Recent studies demonstrated that transfer of encephalitogenic TH17 cells into naïve host animals induces both CXCL1 and CXCR2 expression (Carlson et al., 2008). Furthermore, in relapsing remitting EAE, blockade of CXCR2 resulted in functional improvement and a reduction in leukocyte infiltration. Likewise, CXCR2−/− animals were relatively refractory to disease induction. In this model, the functional deficits are largely a result of immune signaling since transplantation of CXCR2+ leukocytes into CXCR2−/−animals resulted in disease induction. Taken together with the current data from a chronic model of EAE these data strongly suggest that CXCR2 signaling is a major contributor to immune mediated demyelination.

The roles of the chemokine CXCL1 and its receptor CXCR2 in demyelination and remyelination are complex. In a model of demyelination induced by cuprizone intoxication no apparent differences were seen in CXCR2+/+ and CXCR2 null animals (Lindner et al., 2008). The basis for this discrepancy is unclear and may represent either differential mechanisms of demyelination, repair, or the quantitation of recovery. In a more complex transgenic animal model, recent studies suggest that overexpression of CXCL1 driven by the GFAP promoter in astrocytes reduces lesion load and enhances repair in models of relapsing and remitting EAE (Omari et al., 2009). By contrast, in the current studies, blocking CXCR2 signaling enhances recovery in chronic models of EAE and in LPC induced demyelination. Several factors may account for the apparent contradiction in these results. First, in vitro studies demonstrate that the levels of chemokine stimulation are critical in promoting OPC proliferation and inhibiting migration. Dose response analyses demonstrate that at high concentrations of CXCL1, OPC responses are negated, presumably, through receptor desensitization, a common characteristic of chemokine receptors (Mueller et al., 1997; Richmond et al., 1997). Thus, in the setting of EAE, astrocytes are highly responsive and, presumably, the levels of CXCL1 are highly elevated. This might be expected to lead to a transient stimulation of OPC proliferation while more persistent high level ligand expression leads to desensitization of the receptor facilitating functional recovery in relapsing EAE (Richmond et al., 1997). Elevated levels of CXCL1 may stimulate receptors other than CXCR2. For example, while CXCR2 is the major receptor for CXCL1, there is substantial promiscuity in ligand receptor interactions and other receptors such as CXCR1 are known to bind the ligand. The functional role of these alternate receptors is currently unknown. Finally, although overexpression of CXCL1 by oligodendrocytes leads to leukocyte accumulation in the CNS (Smith et al., 1983; Omari et al., 2009), overexpression in astrocytes did not appear to do so. Thus, the effect of the chemokine in this model may be restricted to specific regions of the CNS parenchyma that harbor differentially responsive cells.

We propose several characteristics that position CXCR2 as an attractive target for therapeutic development in demyelinating diseases such as multiple sclerosis. The receptor influences response in OPCs, the primary target cells mediating repair, as well as in peripheral leukocytes, the primary effector cells in immune mediated demyelination. In addition, CXCR2 antagonists have been utilized as potential therapeutics in other inflammatory based diseases (Keane et al., 2004; Gorio et al., 2007). For example, clinical trials are currently ongoing to evaluate CXCR2 antagonists for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis based on the modulation of neutrophil function (Barnes, 2001; Traves et al., 2004; Govindaraju et al., 2006). Taken together, current data suggests that CXCR2 antagonists may enhance myelin repair in demyelinating diseases such as multiple sclerosis.


This research is supported by NIH grant #NS36674 and the Myelin Repair Foundation to R.H.M. Special thanks to Saisho Mangla, Abdelmadjid Belkadi, and Midori Hitomi for technical assistance and Anne DeChant and Sara VanDommelen for manuscript preparation.


Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.


  • Antel J. Multiple sclerosis--emerging concepts of disease pathogenesis. J Neuroimmunol. 1999;98:45–48. [PubMed]
  • Bai L, Lennon DP, Eaton V, Maier K, Caplan AI, Miller SD, Miller RH. Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia. 2009 [PMC free article] [PubMed]
  • Bajetto A, Bonavia R, Barbero S, Florio T, Schettini G. Chemokines and their receptors in the central nervous system. Front Neuroendocrinol. 2001;22:147–184. [PubMed]
  • Bambakidis NC, Wang RZ, Franic L, Miller RH. Sonic hedgehog-induced neural precursor proliferation after adult rodent spinal cord injury. J Neurosurg. 2003;99:70–75. [PubMed]
  • Barnes PJ. Cytokine modulators as novel therapies for airway disease. Eur Respir J Suppl. 2001;34:67s–77s. [PubMed]
  • Baumann N, Pham-Dinh D. Biology of oligodendrocyte and myelin in the mammalian central nervous system. Physiol Rev. 2001;81:871–927. [PubMed]
  • Benedict RH, Bobholz JH. Multiple sclerosis. Semin Neurol. 2007;27:78–85. [PubMed]
  • Bjartmar C, Wujek JR, Trapp BD. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J Neurol Sci. 2003;206:165–171. [PubMed]
  • Blakemore WF, Smith PM, Franklin RJ. Remyelinating the demyelinated CNS. Novartis Found Symp. 2000;231:289–298. discussion 298-306. [PubMed]
  • Busch-Petersen J. Small molecule antagonists of the CXCR2 and CXCR1 chemokine receptors as therapeutic agents for the treatment of inflammatory diseases. Curr Top Med Chem. 2006;6:1345–1352. [PubMed]
  • Carlson T, Kroenke M, Rao P, Lane TE, Segal B. The Th17-ELR+ CXC chemokine pathway is essential for the development of central nervous system autoimmune disease. J Exp Med. 2008;205:811–823. [PMC free article] [PubMed]
  • Chari DM. Remyelination in multiple sclerosis. Int Rev Neurobiol. 2007;79:589–620. [PubMed]
  • Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med. 2006;354:610–621. [PubMed]
  • Compston A, Coles A. Multiple sclerosis. Lancet. 2002;359:1221–1231. [PubMed]
  • Cross AH, Hashim GA, Raine CS. Adoptive transfer of experimental allergic encephalomyelitis and localization of the encephalitogenic epitope in the SWR mouse. J Neuroimmunol. 1991;31:59–66. [PubMed]
  • Davis FA. Pathophysiology of multiple sclerosis and related clinical implications. Mod Treat. 1970;7:890–902. [PubMed]
  • Fernandez EJ, Lolis E. Structure, function, and inhibition of chemokines. Annu Rev Pharmacol Toxicol. 2002;42:469–499. [PubMed]
  • Filipovic R, Zecevic N. The effect of CXCL1 on human fetal oligodendrocyte progenitor cells. Glia. 2008;56:1–15. [PubMed]
  • Filipovic R, Jakovcevski I, Zecevic N. GRO-alpha and CXCR2 in the human fetal brain and multiple sclerosis lesions. Dev Neurosci. 2003;25:279–290. [PubMed]
  • Flynn G, Maru S, Loughlin J, Romero IA, Male D. Regulation of chemokine receptor expression in human microglia and astrocytes. J Neuroimmunol. 2003;136:84–93. [PubMed]
  • Frohman EM, Eagar T, Monson N, Stuve O, Karandikar N. Immunologic mechanisms of multiple sclerosis. Neuroimaging Clin N Am. 2008;18:577–588. ix. [PubMed]
  • Gorio A, Madaschi L, Zadra G, Marfia G, Cavalieri B, Bertini R, Di Giulio AM. Reparixin, an inhibitor of CXCR2 function, attenuates inflammatory responses and promotes recovery of function after traumatic lesion to the spinal cord. J Pharmacol Exp Ther. 2007;322:973–981. [PubMed]
  • Govindaraju V, Michoud MC, Al-Chalabi M, Ferraro P, Powell WS, Martin JG. Interleukin-8: novel roles in human airway smooth muscle cell contraction and migration. Am J Physiol Cell Physiol. 2006;291:C957–965. [PubMed]
  • Hesselgesser J, Horuk R. Chemokine and chemokine receptor expression in the central nervous system. J Neurovirol. 1999;5:13–26. [PubMed]
  • Hohol MJ, Olek MJ, Orav EJ, Stazzone L, Hafler DA, Khoury SJ, Dawson DM, Weiner HL. Treatment of progressive multiple sclerosis with pulse cyclophosphamide/methylprednisolone: response to therapy is linked to the duration of progressive disease. Mult Scler. 1999;5:403–409. [PubMed]
  • Imitola J, Raddassi K, Park KI, Mueller FJ, Nieto M, Teng YD, Frenkel D, Li J, Sidman RL, Walsh CA, Snyder EY, Khoury SJ. Directed migration of neural stem cells to sites of CNS injury by the stromal cell-derived factor 1alpha/CXC chemokine receptor 4 pathway. Proc Natl Acad Sci U S A. 2004;101:18117–18122. [PubMed]
  • Kadi L, Selvaraju R, de Lys P, Proudfoot AE, Wells TN, Boschert U. Differential effects of chemokines on oligodendrocyte precursor proliferation and myelin formation in vitro. J Neuroimmunol. 2006;174:133–146. [PubMed]
  • Katancik JA, Sharma A, de Nardin E. Interleukin 8, neutrophil-activating peptide-2 and GRO-alpha bind to and elicit cell activation via specific and different amino acid residues of CXCR2. Cytokine. 2000;12:1480–1488. [PubMed]
  • Keane MP, Belperio JA, Xue YY, Burdick MD, Strieter RM. Depletion of CXCR2 inhibits tumor growth and angiogenesis in a murine model of lung cancer. J Immunol. 2004;172:2853–2860. [PubMed]
  • Laing KJ, Secombes CJ. Chemokines. Dev Comp Immunol. 2004;28:443–460. [PubMed]
  • Lindner M, Trebst C, Heine S, Skripuletz T, Koutsoudaki PN, Stangel M. The chemokine receptor CXCR2 is differentially regulated on glial cells in vivo but is not required for successful remyelination after cuprizone-induced demyelination. Glia. 2008;56:1104–1113. [PubMed]
  • Liu T, Young PR, McDonnell PC, White RF, Barone FC, Feuerstein GZ. Cytokine-induced neutrophil chemoattractant mRNA expressed in cerebral ischemia. Neurosci Lett. 1993;164:125–128. [PubMed]
  • Luo Y, Fischer FR, Hancock WW, Dorf ME. Macrophage inflammatory protein-2 and KC induce chemokine production by mouse astrocytes. J Immunol. 2000;165:4015–4023. [PubMed]
  • McFarland HF, Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol. 2007;8:913–919. [PubMed]
  • Mi S, Miller RH, Lee X, Scott ML, Shulag-Morskaya S, Shao Z, Chang J, Thill G, Levesque M, Zhang M, Hession C, Sah D, Trapp B, He Z, Jung V, McCoy JM, Pepinsky RB. LINGO-1 negatively regulates myelination by oligodendrocytes. Nat Neurosci. 2005;8:745–751. [PubMed]
  • Miller A, Shapiro S, Gershtein R, Kinarty A, Rawashdeh H, Honigman S, Lahat N. Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J Neuroimmunol. 1998;92:113–121. [PubMed]
  • Miller DH, Molyneux PD, Barker GJ, MacManus DG, Moseley IF, Wagner K. Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secondary progressive multiple sclerosis. Ann Neurol. 1999;46:850–859. [PubMed]
  • Miller RH. Regulation of oligodendrocyte development in the vertebrate CNS. Prog Neurobiol. 2002;67:451–467. [PubMed]
  • Mueller SG, White JR, Schraw WP, Lam V, Richmond A. Ligand-induced desensitization of the human CXC chemokine receptor-2 is modulated by multiple serine residues in the carboxyl-terminal domain of the receptor. J Biol Chem. 1997;272:8207–8214. [PubMed]
  • Nashmi R, Fehlings MG. Mechanisms of axonal dysfunction after spinal cord injury: with an emphasis on the role of voltage-gated potassium channels. Brain Res Brain Res Rev. 2001;38:165–191. [PubMed]
  • Nguyen D, Stangel M. Expression of the chemokine receptors CXCR1 and CXCR2 in rat oligodendroglial cells. Brain Res Dev Brain Res. 2001;128:77–81. [PubMed]
  • Omari KM, John GR, Sealfon SC, Raine CS. CXC chemokine receptors on human oligodendrocytes: implications for multiple sclerosis. Brain. 2005;128:1003–1015. [PubMed]
  • Omari KM, John G, Lango R, Raine CS. Role for CXCR2 and CXCL1 on glia in multiple sclerosis. Glia. 2006;53:24–31. [PubMed]
  • Omari KM, Lutz SE, Santambrogio L, Lira SA, Raine CS. Neuroprotection and remyelination after autoimmune demyelination in mice that inducibly overexpress CXCL1. Am J Pathol. 2009;174:164–176. [PubMed]
  • Ousman SS, David S. Lysophosphatidylcholine induces rapid recruitment and activation of macrophages in the adult mouse spinal cord. Glia. 2000;30:92–104. [PubMed]
  • Padovani-Claudio DA, Liu L, Ransohoff RM, Miller RH. Alterations in the oligodendrocyte lineage, myelin, and white matter in adult mice lacking the chemokine receptor CXCR2. Glia. 2006;54:471–483. [PubMed]
  • Richmond A, Mueller S, White JR, Schraw W. C-X-C chemokine receptor desensitization mediated through ligand-enhanced receptor phosphorylation on serine residues. Methods Enzymol. 1997;288:3–15. [PubMed]
  • Robinson S, Tani M, Strieter RM, Ransohoff RM, Miller RH. The chemokine growth-regulated oncogene-alpha promotes spinal cord oligodendrocyte precursor proliferation. J Neurosci. 1998;18:10457–10463. [PubMed]
  • Robinson S, Cohen M, Prayson R, Ransohoff RM, Tabrizi N, Miller RH. Constitutive expression of growth-related oncogene and its receptor in oligodendrogliomas. Neurosurgery. 2001;48:864–873. discussion 873-864. [PubMed]
  • Smith DF, Galkina E, Ley K, Huo Y. GRO family chemokines are specialized for monocyte arrest from flow. Am J Physiol Heart Circ Physiol. 2005;289:H1976–1984. [PubMed]
  • Smith ME, Somera FP, Eng LF. Immunocytochemical staining for glial fibrillary acidic protein and the metabolism of cytoskeletal proteins in experimental allergic encephalomyelitis. Brain Res. 1983;264:241–253. [PubMed]
  • Spanaus KS, Nadal D, Pfister HW, Seebach J, Widmer U, Frei K, Gloor S, Fontana A. C-X-C and C-C chemokines are expressed in the cerebrospinal fluid in bacterial meningitis and mediate chemotactic activity on peripheral blood-derived polymorphonuclear and mononuclear cells in vitro. J Immunol. 1997;158:1956–1964. [PubMed]
  • Sue RD, Belperio JA, Burdick MD, Murray LA, Xue YY, Dy MC, Kwon JJ, Keane MP, Strieter RM. CXCR2 is critical to hyperoxia-induced lung injury. J Immunol. 2004;172:3860–3868. [PubMed]
  • Tanabe S, Heesen M, Berman MA, Fischer MB, Yoshizawa I, Luo Y, Dorf ME. Murine astrocytes express a functional chemokine receptor. J Neurosci. 1997;17:6522–6528. [PubMed]
  • Tani M, Fuentes ME, Peterson JW, Trapp BD, Durham SK, Loy JK, Bravo R, Ransohoff RM, Lira SA. Neutrophil infiltration, glial reaction, and neurological disease in transgenic mice expressing the chemokine N51/KC in oligodendrocytes. J Clin Invest. 1996;98:529–539. [PMC free article] [PubMed]
  • Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci. 2008;31:247–269. [PubMed]
  • Traves SL, Smith SJ, Barnes PJ, Donnelly LE. Specific CXC but not CC chemokines cause elevated monocyte migration in COPD: a role for CXCR2. J Leukoc Biol. 2004;76:441–450. [PubMed]
  • Tsai HH, Frost E, To V, Robinson S, Ffrench-Constant C, Geertman R, Ransohoff RM, Miller RH. The chemokine receptor CXCR2 controls positioning of oligodendrocyte precursors in developing spinal cord by arresting their migration. Cell. 2002;110:373–383. [PubMed]
  • Valles A, Grijpink-Ongering L, de Bree FM, Tuinstra T, Ronken E. Differential regulation of the CXCR2 chemokine network in rat brain trauma: implications for neuroimmune interactions and neuronal survival. Neurobiol Dis. 2006;22:312–322. [PubMed]
  • Waxman SG. Conduction in myelinated, unmyelinated, and demyelinated fibers. Arch Neurol. 1977;34:585–589. [PubMed]
  • Woodruff RH, Fruttiger M, Richardson WD, Franklin RJ. Platelet-derived growth factor regulates oligodendrocyte progenitor numbers in adult CNS and their response following CNS demyelination. Mol Cell Neurosci. 2004;25:252–262. [PubMed]
  • Zatta P, Raso M, Zambenedetti P, Wittkowski W, Messori L, Piccioli F, Mauri PL, Beltramini M. Copper and zinc dismetabolism in the mouse brain upon chronic cuprizone treatment. Cell Mol Life Sci. 2005;62:1502–1513. [PubMed]